TY - JOUR
T1 - The effect of air pollution on COVID-19 severity in a sample of patients with multiple sclerosis
AU - MuSC-19 study group
AU - Bergamaschi, Roberto
AU - Ponzano, Marta
AU - Schiavetti, Irene
AU - Carmisciano, Luca
AU - Cordioli, Cinzia
AU - Filippi, Massimo
AU - Radaelli, Marta
AU - Immovilli, Paolo
AU - Capobianco, Marco
AU - De Rossi, Nicola
AU - Brichetto, Giampaolo
AU - Cocco, Eleonora
AU - Scandellari, Cinzia
AU - Cavalla, Paola
AU - Pesci, Ilaria
AU - Zito, Antonio
AU - Confalonieri, Paolo
AU - Marfia, Girolama Alessandra
AU - Perini, Paola
AU - Inglese, Matilde
AU - Trojano, Maria
AU - Brescia Morra, Vincenzo
AU - Pisoni, Enrico
AU - Tedeschi, Gioacchino
AU - Comi, Giancarlo
AU - Battaglia, Mario Alberto
AU - Patti, Francesco
AU - Salvetti, Marco
AU - Sormani, Maria Pia
AU - Abbadessa, Gianmarco
AU - Aguglia, Umberto
AU - Allegorico, Lia
AU - Allegri, Rossi Beatrice Maria
AU - Alteno, Anastasia
AU - Amato, Maria Pia
AU - Annovazzi, Pietro
AU - Antozzi, Carlo
AU - Appendino, Lucia
AU - Arena, Sebastiano
AU - Baione, Viola
AU - Balgera, Roberto
AU - Barcella, Valeria
AU - Baroncini, Damiano
AU - Barrilà, Caterina
AU - Battaglia, Mario A.
AU - Bellacosa, Alessandra
AU - Bellucci, Gianmarco
AU - Bergamaschi, Valeria
AU - Bezzini, Daiana
AU - Biolzi, Beatrice
N1 - Funding Information:
R. Bergamaschi has served on scientific advisory boards for Biogen, Merck‐Serono, Novartis, Sanofi‐Genzyme; received research support from Almirall, Bayer, Biogen, Merck‐Serono, Novartis, Sanofi‐Genzyme; received support for travel and congress from Biogen, Roche, Merck‐Serono, Sanofi‐Genzyme, Teva; received honoraria for speaking engagements from Biogen, Merck‐Serono, Novartis, Sanofi‐Genzyme. M. Filippi is Editor‐in‐Chief of the , Associate Editor of , Associate Editor of and Associate Editor of ; received compensation for consulting services and/or speaking activities from Alexion, Almirall, Bayer, Biogen, Celgene, Eli Lilly, Genzyme, Merck‐Serono, Novartis, Roche, Sanofi, Takeda and Teva Pharmaceutical Industries; and receives research support from Biogen Idec, Merck‐Serono, Novartis, Roche, Teva Pharmaceutical Industries, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla and ARiSLA (Fondazione Italiana di Ricerca per la SLA). He received speaker honoraria from the following companies: Biogen, Merck, Novartis, Roche, Sanofi‐Genzyme and TEVA. M. Radaelli received speaker honoraria from Biogen Idec, Sanofi‐Genzyme, Novartis and Merck Serono and funding for travel to scientific meetings from Biogen Idec, Sanofi‐Genzyme, Novartis, Merck Serono, Teva and Roche. P. Immovilli reports personal fees from Roche, personal fees from Biogen, personal fees from Merck, outside the submitted work. M. Capobianco reports personal fees and non‐financial support from Biogen, personal fees and non‐financial support from Merck Serono, personal fees and non‐financial support from Roche, personal fees and non‐financial support from Novartis, personal fees and non‐financial support from Sanofi, personal fees from Almirall, outside the submitted work. N. De Rossi received speaker honoraria from Biogen Idec, Genzyme, Novartis, Sanofi‐Aventis; received funding for participation in advisory boards to Novartis, Biogen and Genzyme‐Sanofi and for travel to scientific meetings from Biogen Idec, Teva, Sanofi‐Genzyme, Roche, Almirall and Novartis. P. Confalonieri has received honoraria for speaking or consultation fees from Novartis and Biogen, has received funding for travel to attend scientific events or speaker honoraria from Merck Serono, Biogen Idec, Teva and Roche. He has also received institutional research support from Merk Serono, Novartis and Roche. He is also principal investigator in clinical trials for Biogen, Merck Serono, Roche. M. Inglese received research grants from NIH, DOD, NMSS, FISM and Teva Neuroscience; received fees for participating in advisory boards from Roche, Biogen, Merck and Genzyme. M. Trojano reports grants and personal fees from Biogen, grants and personal fees from Novartis, grants and personal fees from Roche, grants and personal fees from Merck, personal fees from Sanofi, personal fees from TEVA, outside the submitted work. V. Brescia Morra has received funding for travel, speaker honoraria, advisory board and research support from Merck Serono, Novartis, Biogen Idec, TEVA, Genzyme, Roche, Bayer, Almirall. G. Comi reports personal fees from Novartis, Teva Pharmaceutical Industries Ltd, Teva Italia Srl, Sanofi Genzyme, Genzyme Corporation, Genzyme Europe, Merck KGaA, Merck Serono SpA, Celgene Group, Biogen Idec, Biogen Italia Srl, F. Hoffman‐La Roche, Roche SpA, Almirall SpA, Forward Pharma, Medday, Excemed, outside the submitted work. F. Patti reports grants from Biogen, grants from Merck, grants from FISM, grants from Onlus association, grants from University of Catania, personal fees from Almirall, personal fees from Bayer, personal fees from Biogen, personal fees from Merck, personal fees from Roche, personal fees from Sanofi, personal fees from TEVA, outside the submitted work. M. Salvetti reports grants and personal fees from Biogen, grants and personal fees from Merck, grants and personal fees from Novartis, grants and personal fees from Roche, grants and personal fees from Sanofi, grants and personal fees from Teva, grants from Italian Multiple Sclerosis Foundation, grants from Sapienza University of Rome, outside the submitted work. M.P. Sormani reports grants from Roche, during the conduct of the study; personal fees from Biogen, Merck, Roche, Sanofi, Novartis, Medday, Geneuro, Celgene, Mylan outside the submitted work. M. Ponzano, I. Schiavetti, L. Carmisciano, C. Cordioli, G. Brichetto, E. Cocco, C. Scandellari, P. Cavalla, I. Pesci, A. Zito, G.A. Marfia, P. Perini, E. Pisoni, G. Tedeschi, M.A. Battaglia have nothing to disclose. Journal of Neurology Human Brain Mapping Radiology Neurological Sciences
Publisher Copyright:
© 2021 European Academy of Neurology.
PY - 2022/2/1
Y1 - 2022/2/1
N2 - Background and purpose: Some studies have shown that air pollution, often assessed by thin particulate matter with diameter below 2.5 µg/m3 (PM2.5), may contribute to severe COVID-19 courses, as well as play a role in the onset and evolution of multiple sclerosis (MS). However, the impact of air pollution on COVID-19 has never been explored specifically amongst patients with MS (PwMS). This retrospective observational study aims to explore associations between PM2.5 and COVID-19 severity amongst PwMS. Methods: Data were retrieved from an Italian web-based platform (MuSC-19) which includes PwMS with COVID-19. PM2.5 2016–2018 average concentrations were provided by the Copernicus Atmospheric Monitoring Service. Italian patients inserted in the platform from 15 January 2020 to 9 April 2021 with a COVID-19 positive test were included. Ordered logistic regression models were used to study associations between PM2.5 and COVID-19 severity. Results: In all, 1087 patients, of whom 13% required hospitalization and 2% were admitted to an intensive care unit or died, were included. Based on the multivariate analysis, higher concentrations of PM2.5 increased the risk of worse COVID-19 course (odds ratio 1.90; p = 0.009). Conclusions: Even if several other factors explain the unfavourable course of COVID-19 in PwMS, the role of air pollutants must be considered and further investigated.
AB - Background and purpose: Some studies have shown that air pollution, often assessed by thin particulate matter with diameter below 2.5 µg/m3 (PM2.5), may contribute to severe COVID-19 courses, as well as play a role in the onset and evolution of multiple sclerosis (MS). However, the impact of air pollution on COVID-19 has never been explored specifically amongst patients with MS (PwMS). This retrospective observational study aims to explore associations between PM2.5 and COVID-19 severity amongst PwMS. Methods: Data were retrieved from an Italian web-based platform (MuSC-19) which includes PwMS with COVID-19. PM2.5 2016–2018 average concentrations were provided by the Copernicus Atmospheric Monitoring Service. Italian patients inserted in the platform from 15 January 2020 to 9 April 2021 with a COVID-19 positive test were included. Ordered logistic regression models were used to study associations between PM2.5 and COVID-19 severity. Results: In all, 1087 patients, of whom 13% required hospitalization and 2% were admitted to an intensive care unit or died, were included. Based on the multivariate analysis, higher concentrations of PM2.5 increased the risk of worse COVID-19 course (odds ratio 1.90; p = 0.009). Conclusions: Even if several other factors explain the unfavourable course of COVID-19 in PwMS, the role of air pollutants must be considered and further investigated.
KW - air pollution
KW - coronavirus
KW - multiple sclerosis
UR - http://www.scopus.com/inward/record.url?scp=85119041633&partnerID=8YFLogxK
U2 - 10.1111/ene.15167
DO - 10.1111/ene.15167
M3 - Article
C2 - 34735749
AN - SCOPUS:85119041633
SN - 1351-5101
VL - 29
SP - 535
EP - 542
JO - European Journal of Neurology
JF - European Journal of Neurology
IS - 2
ER -